



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
<i>RR</i>	AA-1	5,650,135	July 22, 1997	Contag et al.			
<i>1</i>	AB-1	6,020,121	February 1, 2001	Bao et al.			
<i>RR</i>	AC-1	6,217,847	April 17, 2000	Contag et al.			

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES	NO
<i>RR</i>	AD-1	WO 94/11499	May 26, 1994	PCT				
<i>1</i>	AE-1	WO 96/40979 A1	December 19, 1996	PCT				
<i>1</i>	AF-1	WO 97/00957	January 9, 1997	PCT				
<i>1</i>	AG-1	WO 97/11690 A2, A3	April 3, 1997	PCT				
<i>1</i>	AH-1	WO 97/18841	May 29, 1997	PCT				
<i>1</i>	AI-1	WO 97/40381 A1	October 30, 1997	PCT				
<i>1</i>	AJ-1	WO 98/28971	July 9, 1998	PCT				
<i>RR</i>	AK-1	WO 98/30715	July 16, 1998	PCT				

Examiner:

*RRS*

Date Considered:

*2/2/04*

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 2 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

RLS	AL-1	WO 98/55638	December 10, 1998	PCT					
1	AM-1	WO 00/08726	February 17, 2000	PCT					
	AN-1	WO 00/36106	June 22, 2000	PCT					
	AO-1	WO 00/54581 A2,A3	September 21, 2000	PCT					
	AP-1	WO 01/18195 A2	March 15, 2001	PCT					
	AQ-1	WO 01/18225 A1	March 15, 2001	PCT					
RLS	AR-1	WO 01/37195 A2	May 25, 2001	PCT					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
RLS	AS-1	Aiello et al., "Suppression of Retinal Neovascularization <i>in Vivo</i> by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>92</u> :10457-10461 (1995)
	AT-1	Asahara et al., "Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization," <i>Circ. Res.</i> <u>85</u> :221-228 (1999)
RLS	AU-1	Bais et al., "G-Protein-Coupled Receptor of Kaposi's Sarcoma-Associated Herpes Virus is a Viral Oncogene and Angiogenesis Activator," <i>Nature</i> <u>391</u> :86-89 (1998)

Examiner:

RLS

Date Considered:

2/2/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 3 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

Exam. Init.	Ref. Desig.	Description
RM	AV-1	Benjamin et al., "Conditional Switching of Vascular Endothelial Growth Factor (VEGF) Expression in Tumors: Induction of Endothelial Cell Shedding and Regression of Hemangioblastoma-Like Vessels by VEGF Withdrawal," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>94</u> :8761-8766 (1997)
	AW-1	Berse, B., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," <i>Molecular Biology of the Cell</i> <u>3</u> :211-220 (1992)
	AX-1	Contag et al., "Visualizing Gene Expression Living Mammals Using a Bioluminescent Reporter," <i>Photochemistry and Photobiology</i> <u>66</u> (4):523-531 (1997)
	AY-1	Disalvo et al., "Purification and Characterization of Naturally Occurring Vascular Endothelial Growth Factor-Placenta Growth Factor Heterodimer," <i>The Journal of Biological Chemistry</i> <u>270</u> (13):7717-7723 (1995)
	AZ-1	Dumont, et al., "Dominant-Negative and Targeted Null Mutations in the Endothelial Receptor Tyrosine Kinase, <i>Tek</i> , Reveal a Critical Role in Vasculogenesis of the Embryo," <i>Genes &amp; Development</i> <u>8</u> :1897-1909 (1994)
	BA-1	Dvorak et al., "Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels," <i>J. Exp. Med.</i> <u>174</u> :1275-1278 (1991)
	BB-1	Ferrara et al., "The Biology of Vascular Endothelial Growth Factor," <i>Endocr. Rev.</i> <u>18</u> (1):4-25 (1997)
RM	BC-1	Ferrara et al., "Heterozygous Embryonic Lethality Inducted by Targeted Inactivation of the VEGF Gene," <i>Nature</i> <u>380</u> :439-442 (1996)

Examiner:

RM

Date Considered:

2/2/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 4 of 8

RECEIVED  
JAN 16 2002  
TECH UNIT 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

Exam. Init.	Ref. Desig.	Description
RLS	BD-1	Fong et al., "SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types," <i>Cancer Research</i> <u>59</u> :99-106 (1999)
	BE-1	Forsythe et al., "Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1," <i>Molecular and Cellular Biology</i> <u>16</u> (9):4604-4613 (1996)
	BF-1	Fukumura et al., "Tumor Induction of VEGF Promoter Activity in Stromal Cells," <i>Cell</i> <u>94</u> :715-725 (1998)
	BG-1	Hanahan, D., "Signaling Vascular Morphogenesis and Maintenance," <i>Science</i> <u>277</u> :48-50 (1997)
	BH-1	Ikeda et al., "Hypoxia-Induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells," <i>The Journal of Biological Chemistry</i> <u>270</u> (34):19761-19765 (1995)
	BI-1	Jain, R.K., "Endothelial Cell Death, Angiogenesis, and Microvascular Function After Castration in an Androgen-Dependent Tumor: Role of Vascular Endothelial Growth Factor," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>95</u> :10820-10825 (1998)
	BJ-1	Jeltsch et al., "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," <i>Science</i> <u>276</u> :1423-1425 (1997)
RLS	BK-1	Kaipainen et al., "Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas," <i>Cancer Research</i> <u>54</u> :6571-6577 (1994)

Examiner:

RLS

Date Considered:

2/2/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 5 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

Exam. Init.	Ref. Desig.	Description
209	BL-1	Kappel et al., "Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 ( <i>Flk-1</i> ) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice," <i>Blood</i> <u>83</u> (12):4284-4292 (1999)
	BM-1	Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth <i>In Vivo</i> ," <i>Nature</i> <u>362</u> :841-844 (1993)
	BN-1	Kitsukawa et al., "Overexpression of Membrane Protein, Neuropilin, in Chimeric Mice Causes Anomalies in the Cardiovascular System, Nervous System and Limbs," <i>Development</i> <u>121</u> :4309-4318 (1995)
	BO-1	Larcher et al., "VEGF/VPF Overexpression in Skin of Transgenic Mice Induces Angiogenesis, Vascular Hyperpermeability and Accelerated Tumor Development," <i>Oncogene</i> <u>17</u> :303-311 (1998)
	BP-1	Millauer, B., "High Affinity VEGF Binding and Developmental Expression Suggest <i>Flk-1</i> as a Major Regulator of Vasculogenesis and Angiogenesis," <i>Cell</i> <u>72</u> :835-846 (1993)
	BQ-1	Millauer, B., "Glioblastoma Growth Inhibited <i>In Vivo</i> by a Dominant-Negative <i>Flk-1</i> Mutant," <i>Nature</i> <u>367</u> :576-579 (1994)
	BR-1	Millauer, B., "Dominant-Negative Inhibition of <i>Flk-1</i> Suppresses the Growth of Many Tumor Types <i>In Vivo</i> ," <i>Cancer Res.</i> <u>56</u> :1615-1620 (1996)
219	BS-1	Mukhopadhyay et al., "Wild-Type p53 and v-Src Exert Opposing Influences on Human Vascular Endothelial Growth Factor Gene Expression," <i>Cancer Res.</i> <u>55</u> :6161-6165 (1995)

Examiner:

219

Date Considered:

2/2/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 6 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

Exam. Init.	Ref. Desig.	Description
<u>219</u>	BT-1	Mukhopadhyay et al., "Hypoxic Induction of Human Vascular Endothelial Growth Factor Expression Through c-Src Activation," <i>Nature</i> <u>375</u> :577-581 (1995)
	BU-1	Oh et al., "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lyphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," <i>Developmental Biology</i> <u>188</u> :96-109 (1997)
	BV-1	Okamoto et al., "Transgenic Mice With Increased Expression of Vascular Endothelial Growth Factor in the Retinal," <i>American Journal Pathology</i> <u>151</u> :281-291 (1997)
	BW-1	Olofason et al., "Vascular Endothelial Growth Factor B, a Novel Growth Factor for Endothelial Cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>93</u> :2576-2581 (1996)
	BX-1	Patterson et al., "Cloning and Functional Analysis of the Promoter for KDR/flk-1, a Receptor for Vascular Endothelial Growth Factor," <i>The Journal of Biological Chemistry</i> <u>270</u> (39):23111-23118 (1995)
	BY-1	Plate et al., "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas <i>In Vivo</i> ," <i>Nature</i> <u>359</u> :845-848 (1992)
	BZ-1	Plate et al., "Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis," <i>Cancer Research</i> <u>53</u> :5822-5827 (1993)
	CA-1	Puri et al., "The Receptor Tyrosine Kinase TIE is Required for Integrity and Survival of Vascular Endothelial Cells," <i>EMBO Journal</i> <u>14</u> (23):5884-5891 (1995)
<u>219</u>	CB-1	Röncke et al., "Characterization of the Endothelium-Specific Murine Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter," <i>Circulation Research</i> <u>79</u> (2):277-285 (1996)

Examiner:

219

Date Considered:

2/2/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 7 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

Exam. Init.	Ref. Desig.	Description
R29	CC-1	Shalaby et al., "Failure of Blood-Island Formation and Vasculogenesis in Flk-1-Deficient Mice," <i>Nature</i> <u>376</u> :62-65 (1995)
/	CD-1	Sheweiki et al., "Vascular Endothelial Growth Factor Induced by Hypoxia may Mediate Hypoxia-Initiated Angiogenesis," <i>Nature</i> <u>359</u> :843-845 (1992)
/	CE-1	Sheweiki et al., "Induction of Vascular Endothelial Growth Factor Expression by Hypoxia and by Glucose Deficiency in Multicell Spheroids: Implications for Tumor Angiogenesis," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>92</u> :768-772 (1995)
/	CF-1	Siemeister et al., "An Antagonistic Vascular Endothelial Growth Factor (VEGF) Variant Inhibits VEGF-Stimulated Receptor Autophosphorylation and Proliferation of Human Endothelial Cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>95</u> :4625-4629 (1998)
/	CG-1	Soker et al., "Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor," <i>Cell</i> <u>92</u> :735-745 (1998)
/	CH-1	Soker et al., "Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells that Bind VEGF <sub>188</sub> Via Its Exon 7-Encoded Domain," <i>Journal of Biological Chemistry</i> <u>271</u> :5761-5767 (1996)
/	CI-1	Soker et al., "Inhibition of Vascular Endothelial Growth Factor (VEGF)-Induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF <sub>188</sub> ," <i>Journal of Biological Chemistry</i> <u>272</u> (50):31582-31588 (1997)
R29	CJ-1	Stratman, A., "Cell Type-Specific Expression of Angiopoietin-1 and Angiopoietin-2 Suggests a Role in Glioblastoma Angiogenesis," <i>American Journal of Pathology</i> <u>153</u> (5):1459-1466 (1998)

Examiner:

R29

Date Considered:

2/2/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty Dkt No. 9400-0003.20  
PXE-012.US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 8 of 8

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

In the Application of ZHANG et al.

Serial No.: 09/465,978

Art Unit: 1632

Filed: December 16, 1999

Examiner: R. Shukla

Title: METHODS AND COMPOSITIONS FOR SCREENING FOR ANGIOGENESIS MODULATING COMPOUNDS

Exam. Init.	Ref. Desig.	Description
<i>202</i>	CK-1	Suri et al., "Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, During Embryonic Angiogenesis," <i>Cell</i> <u>87</u> :1171-1180 (1996)
	CL-1	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <i>Cancer Res.</i> <u>54</u> :4233-4237 (1994)
	CM-1	Terman et al., "Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," <i>Oncogene Sept.</i> <u>6</u> (9):1677-1683 (1991)
	CN-1	Tischer et al., "The Human Gene for Vascular Endothelial Growth Factor," <i>Journal of Biological Chemistry</i> : <u>266</u> (18):11947-11954 (1991)
	CO-1	Waltenberger, J., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," <i>Journal of Biological Chemistry</i> <u>269</u> :26988-26995 (1995)
	CP-1	Yoshiji et al., "Vascular Endothelial Growth Factor is Essential for Initial but not Continued <i>in Vivo</i> Growth of Human Breast Carcinoma Cells," <i>Cancer Research</i> <u>57</u> :3924-3928 (1997)
<i>202</i>	CQ-1	Yuan et al., "Time-Dependent Vascular Regression and Permeability Changes in Established Human Tumor Xenografts Induced by an Anti-Vascular Endothelial Growth Factor/Vascular Permeability Factor Antibody," <i>Proc. Natl. Acad. Sci. U.S.A.</i> <u>93</u> :14765-14770 (1996)

Examiner:

*RM*

Date Considered:

*2/4/04*

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.